MET and Miyoshi myopathy: Overall, these results suggest that, although aberrations of BAP1, CDKN2A, and other tumor suppressor genes are the commonest genomic cancer-driving hits in MM [7,8,9], some rare cases of MM might also be driven by genomic dysregulation of MET signaling.